<DOC>
	<DOCNO>NCT01173913</DOCNO>
	<brief_summary>Oral administration many advantage intravenously administrate drug patient . Up , oral administration docetaxel single agent feasible due low variable bioavailability . This low systematic exposure docetaxel effectively increase co-administration ritonavir . The department pharmacy Slotervaart Hospital Netherlands Cancer Institute develop solid oral dosage form docetaxel , ModraDoc001 10 mg capsule . Two novel dosage form docetaxel improved pharmaceutical characteristic , develop : ModraDoc003 10 mg tablet ModraDoc004 10/50 mg tablet . The systemic exposure administration form investigate .</brief_summary>
	<brief_title>Weekly Administration ( bi- ) Daily Oral Docetaxel Combination With Ritonavir</brief_title>
	<detailed_description>The bioavailability docetaxel limit due metabolise cytochrome P450 ( CYP ) enzymes , abundantly present gastrointestinal tract . Inhibition CYP3A4 enzymes ritonavir ( anti-retroviral drug ) previously conduct proof-of-concept phase I trial , proven enhance bioavailability oral docetaxel . Oral administration docetaxel investigate five clinical trial , initiated Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital ( NKI-AVL ) . The department pharmacy Slotervaart Hospital Netherlands Cancer Institute develop solid oral dosage form docetaxel , ModraDoc001 10 mg capsule . This formulation investigate 40 patient first clinical study . The preliminary result ModraDoc001 10mg promise linearity systemic exposure docetaxel apply dose ModraDoc001 10mg capsule see . In attempt improve prolong systemic exposure explore twice daily dose schedule . Two novel dosage form docetaxel , ModraDoc003 10 mg tablet ModraDoc004 10/50 mg tablet , develop . Both spray-dried solid dispersion docetaxel press tablet . The distinction ritonavir include co-formulation ModraDoc004 10/50 mg tablet ( 10 mg docetaxel 50 mg ritonavir ) . Both dosage form investigate arm B see whether new formulation comparable pharmacokinetic characteristic docetaxel capsule formulation . Arm A Arm A dose escalation study establish maximum tolerate dose ( MTD ) weekly bi-daily ModraDoc001 10 mg capsule . This study do classical dose escalation design . The start dose 40 mg BID . This dose base safety weekly 80 mg single dose previously conduct study . Arm B ModraDoc003 10 mg tablet ModraDoc004 10/50 mg tablet investigate arm B see whether new formulation comparable pharmacokinetic characteristic docetaxel capsule formulation od ModraDoc001 10 mg. Another part study screen 2 different polymorphism , C1236T ( MDR1 ) CYP3A4*1B . Polymorphic variant may influence absorption elimination docetaxel ritonavir . Arm D dose escalation study establish maximum tolerate dose ( MTD ) weekly bi-daily ModraDoc006 10 mg tablet . This study do classical dose escalation design . The start dose 20 mg BID . This dose base safety BID weekly ModraDoc001 mg previously conduct arm A .</detailed_description>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<criteria>1 . Histological cytological proof cancer 2 . Patients standard therapy proven benefit exist 3 . Patients might benefit treatment docetaxel , e.g . advanced breast , gastric , esophagus , bladder , ovarian cancer nonsmall cell lung cancer , head neck cancer , prostate cancer carcinoma unknown primary site . 4 . Age _ 18 year 5 . Able willing give write informed consent 6 . Able willing undergo blood sample pharmacokinetics 7 . Life expectancy _ 3 month allow adequate follow toxicity evaluation antitumor activity 8 . Minimal acceptable safety laboratory value ANC _ 1.5 x 109 /L Platelet count _ 100 x 109 /L Hepatic function define serum bilirubin _ 1.5 x ULN , ALAT ASAT _ 2.5 x ULN Renal function define serum creatinine _ 1.5 x ULN creatinine clearance _ 50 ml/min ( CockcroftGault formula ) . 9. WHO performance status _ 2 10 . No radio chemotherapy within last 4 week prior study entry ( palliative limit radiation pain reduction allow ) 11 . Able willing swallow oral medication 1 . Patients known alcoholism , drug addiction and/or psychotic disorder history suitable adequate follow 2 . Women pregnant breast feeding . 3 . Both men woman enrol trial must agree use reliable contraceptive method throughout study ( adequate contraceptive method : condom , sterilization , barrier contraceptive measure preferably combination condom ) . 4 . Concomitant use MDR CYP3A modulate drug Ca+entry blocker ( verapamil , dihydropyridines ) , cyclosporine , quinidine , quinine , tamoxifen , megestrol grapefruit juice , concomitant use HIV medication ; protease inhibitor , ( non ) nucleoside analoga , St. Johns wort macrolide antibiotic erythromycin clarithromycin . 5 . Uncontrolled infectious disease know HIV1 HIV2 type patient 6 . Unresolved ( &gt; grade 1 ) toxicity previous chemotherapy 7 . Bowel obstruction motility disorder may influence absorption drug 8 . Chronic use H2receptor antagonists proton pump inhibitor 9 . Neurologic disease may render patient increase risk peripheral central neurotoxicity 10 . Preexisting neuropathy great CTC grade 1 11 . Symptomatic cerebral leptomeningeal metastases 12 . Evidence disease , neurological metabolic dysfunction , physical examination find laboratory find give reasonable suspicion disease condition contraindicate use investigational drug put patient high risk treatmentrelated complication .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>oral docetaxel</keyword>
	<keyword>ModraDoc</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>safety</keyword>
	<keyword>MTD</keyword>
	<keyword>DLT</keyword>
</DOC>